FDA Delays Decision on Biohaven's Troriluzole for Rare Disease, Plans Advisory Committee Review on May 15, 2025 Advisory Committees Ataxia Biohaven Deferred disease drug Extension Infrequent Neurodegenerative Disorders PDUFA Spinocerebellar troriluzole United States Food and Drug Administration +